GlycanAge is a UK-registered, Croatian-founded longevity biotech that measures biological age by analyzing glycans - sugar molecules attached to immune-system antibodies. Built on roughly two decades of glycobiology research led by Professor Gordan Lauc, the company turns a finger-prick blood sample into a report on how fast a person is aging at the molecular level, plus a specialist consultation to guide lifestyle changes. It sells directly to consumers and is expanding its glycan biomarkers into hospitals and preventive-care systems.

Grace Science, LLC is a Palo Alto-based biotechnology company founded in 2017 by Silicon Valley entrepreneur Matt Wilsey and Nobel laureate chemist Dr. Carolyn Bertozzi to develop therapies built on the biology of NGLY1, an enzyme central to protein quality control. The company grew out of a father's search for a treatment after his daughter Grace was diagnosed with ultra-rare NGLY1 Deficiency. Its lead program, GS-100, is an AAV9 gene replacement therapy now in a Phase 1/2/3 clinical trial and holds FDA RMAT designation. Grace Science also pursues small-molecule and biomarker work that extends NGLY1 biology into oncology and neurodegeneration.
Ganesh Kaundinya is President and CEO of GlycoEra, a Swiss-US biotech building extracellular protein degraders to treat autoimmune disease. An MIT-trained chemical engineer, he co-founded Momenta Pharmaceuticals and helped grow it from a sugar-sequencing concept into a public company with FDA-approved products, later acquired by Johnson & Johnson for $6.5 billion. At GlycoEra he raised an oversubscribed $130 million Series B in 2025 to push a precision IgG4 degrader toward the clinic.